Editorial: Current perspectives in the diagnosis of parathyroid disease, volume II - Takeaways - MDSpire

Editorial: Current perspectives in the diagnosis of parathyroid disease, volume II

  • By

  • Takahisa Hiramitsu

  • Jong Ju Jeong

  • June 16, 2026

  • 0 min

Share

  • 1

    Parathyroid diseases range from asymptomatic biochemical abnormalities to severe conditions with systemic complications.

  • 2

    Recent advances in biochemical assays and imaging have improved detection but challenges in localization and risk stratification remain.

  • 3

    Dynamic biomarker profiling can enhance risk stratification and support personalized treatment strategies for primary hyperparathyroidism.

  • 4

    FCH PET/CT outperforms MIBI SPECT/CT in preoperative localization of parathyroid glands, influencing surgical outcomes.

  • 5

    A predictive model for secondary hyperparathyroidism can estimate phosphorus reduction post-surgery, aiding in patient management.

Original Source(s)

Editorial: Current perspectives in the diagnosis of parathyroid disease, volume II

  • by Takahisa Hiramitsu, Jong Ju Jeong

  • June 16, 2026

Related Content

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

Adrenal metastases of differentiated thyroid cancer: clinicopathological characteristics and prognostic factors

Case Report: Cortical bone loss, impaired mineralization, and reduced adiposity contributing to chronic bone pain in SFRP4-related skeletal disease with an ALPL variant